About Nexvet Biopharma PLC
Nexvet Biopharma public limited company is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing species-specific biologics. The Company's platform technology, which it refers to as PETization, is an algorithmic approach that enables the Company to create monoclonal antibodies (mAbs) a type of biologic, that are designed to be recognized as self or native by an animal's immune system, a property referred to as 100% species-specificity. PETization is designed to build upon the safety and efficacy data from clinically tested human therapies to create new therapies for companion animals. Biologics generally include mAbs, which are targeted antibodies derived from identical (clonal) cells. The Company's advanced product candidates are in pivotal-phase development: ranevetmab (or NV-01) and frunevetmab (or NV-02).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: NVET
- Previous Close: $3.25
- 50 Day Moving Average: $3.43
- 200 Day Moving Average: $4.09
- 52-Week Range: $11,752,000.00 - $2.61
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.91
- P/E Growth: 0.00
- Market Cap: $38.19M
- Outstanding Shares: 11,752,000
- Beta: 0.52
- Return on Equity: -57.98%
- Return on Assets: -50.99%
Companies Related to Nexvet Biopharma PLC:
- Current Ratio: 7.69%
- Quick Ratio: 7.69%
What is Nexvet Biopharma PLC's stock symbol?
Nexvet Biopharma PLC trades on the NASDAQ under the ticker symbol "NVET."
Where is Nexvet Biopharma PLC's stock going? Where will Nexvet Biopharma PLC's stock price be in 2017?
1 analysts have issued 12-month price targets for Nexvet Biopharma PLC's shares. Their forecasts range from $8.00 to $8.00. On average, they anticipate Nexvet Biopharma PLC's stock price to reach $8.00 in the next year.
When will Nexvet Biopharma PLC announce their earnings?
Nexvet Biopharma PLC is scheduled to release their next quarterly earnings announcement on Wednesday, May, 10th 2017.
Who owns Nexvet Biopharma PLC stock?
Nexvet Biopharma PLC's stock is owned by a number of of retail and institutional investors. Top institutional investors include Broadfin Capital LLC (9.61%), Foresite Capital Management II LLC (7.63%), AustralianSuper Pty Ltd (5.93%) and Boxer Capital LLC (1.32%). Company insiders that own Nexvet Biopharma PLC stock include Ashraf Hanna, Cormac G Kilty, David Gearing and Farallon Capital Management Ll.
Who sold Nexvet Biopharma PLC stock? Who is selling Nexvet Biopharma PLC stock?
Nexvet Biopharma PLC's stock was sold by a variety of institutional investors in the last quarter, including Foresite Capital Management II LLC.
Who bought Nexvet Biopharma PLC stock? Who is buying Nexvet Biopharma PLC stock?
Nexvet Biopharma PLC's stock was bought by a variety of institutional investors in the last quarter, including Broadfin Capital LLC. Company insiders that have bought Nexvet Biopharma PLC stock in the last two years include Ashraf Hanna, Cormac G Kilty, David Gearing and Farallon Capital Management Ll.
How do I buy Nexvet Biopharma PLC stock?
Shares of Nexvet Biopharma PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Nexvet Biopharma PLC stock cost?
One share of Nexvet Biopharma PLC stock can currently be purchased for approximately $3.25.